CoChat

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

Open access
Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., Riddle, M. C. · 2015 · Diabetes, Obesity and Metabolism
Cited by 131

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: To compare the efficacy and safety of new insulin glargine 300 U/ml ( Gla ‐300) with insulin glargine 100 U/ml ( Gla ‐100) over 12 months of treatment in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs ( OADs ). Methods: EDITION 2 ( NCT01499095 ) was a randomized, 6‐month, multicentre, open‐label, two‐arm, phase IIIa study investigating once‐daily Gla ‐300 versus Gla ‐100, plus OADs (excluding sulphonylureas), with a 6‐month safety extension. Results: Similar numbers of participants in each group completed 12 months of treatment [ Gla ‐300, 315 participants (78%); Gla ‐100, 314 participants (77%)]. The reduction in glycated haemoglobin was maintained for 12 months with both treatments: least squares ( LS ) mean (standard error) change from baseline −0.55 (0.06)% for G la‐300 and −0.50 (0.06)% for Gla ‐100; LS mean difference −0.06 [95% confidence interval ( CI ) −0.22 to 0.10)%]. A significant relative reduction of 37% in the annualized rate of nocturnal confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia was observed with Gla ‐300 compared with Gla ‐100: rate ratio 0.63 [(95% CI 0.42–0.96); p = 0.031], and fewer participants experienced ≥1 event [relative risk 0.84 (95% CI 0.71–0.99)]. Severe hypoglycaemia was infrequent. Weight gain was significantly lower with Gla ‐300 than Gla ‐100 [ LS mean difference −0.7 (95% CI −1.3 to −0.2) kg; p = 0.009]. Both treatments were well tolerated with a similar pattern of adverse events (incidence of 69 and 60% in the Gla ‐300 and Gla ‐100 groups). Conclusions: In people with type 2 diabetes treated with Gla ‐300 or Gla ‐100, and non‐sulphonylurea OADs , glycaemic control was sustained over 12 months, with less nocturnal hypoglycaemia in the Gla ‐300 group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12532

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 131

Metadata

Authors
Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., & Riddle, M. C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-09-14
Volume
17
Issue
12
Pages
1142-1149
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1726580060
Cited by
131
References
7
FWCI
15.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.